12 results
To study the potential of baclofen as an anti-craving/relapse agent in GHB dependent patients.
To evaluate the safety and tolerability of ascending single and multiple oral doses of ADX71441 as compared to placebo in healthy volunteers.To evaluate the pharmacokinetics of orally administered single and multiple doses of ADX71441 and its…
Primary Objective* To demonstrate the efficacy of adjunctive perampanel therapy, compared to placebo on primary generalized tonic-clonic (PGTC)seizuresSecondary Objectives* To evaluate the safety and tolerability of perampanel in subjects with…
The objective is to determine whether ITB Therapy is more effective than oral anti-spasticity agents in reducing the spasticity.
The primary goal of the present study is to examine the efficacy of high dose baclofen for the treatment of patients with AD in a double-blind, randomized, placebo controlled study. Therefore high dose baclofen will be compared with placebo.…
Primary Objective: The primary objective is to evaluate the efficacy of 2 doses ofperampanel (8 and 12 mg) in comparison to placebo given as an adjunctive therapy insubjects with refractory partial seizures.Secondary Objective: The secondary…
Primary aim of the study is to compare the efficacy and safety of two flowrates of ITB while maintaining a constant daily dose.
The primary objective is to evaluate the safety and tolerability of perampanel (up to12mg/day) given as adjunctive treatment in subjects with refractory partial seizuresThe secondary objective is to evaluate the maintenance of effect of perampanel…
Objectives: The primary aim of this study is to provide evidence for the effect of ITB treatment on the level of activities in dystonic CP patients.
Based on results from a comparative review (Paoletti 2013), we hypothesize that if the toxicity profile and the PK parameters observed in children treated at the adult RP2D are similar to those in adults; escalating to the MTD is not necessarily…
Objective of the phase II POP study:To determine the safety and preliminary anti-tumor activity of AZD1775 in combination with carboplatin in p53 mutated epithelial ovarian cancer in a 21 day schedule.Objectives of the additional safety and…
To determine the maximum tolerable dose of the combination therapy of weekly carboplatin with the Wee-1 inhibitor AZD1775Secondary:To determine the pharmacokinetics of the combination therapy of weekly carboplatin combined with AZD1775To investigate…